ClinicalTrials.gg
Active, not recruitingNCT06082167STELLAR-305Updated Aug 17, 2025

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2/3 interventional study of Zanzalintinib and Zanzalintinib-matched Placebo in Head and Neck Squamous Cell Carcinoma, sponsored by Exelixis. Active, not recruiting at 168 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Exelixis · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Squamous Cell Carcinoma of Head and Neck with a site in Brazil — 7 open to participants now, 16 under way, 10 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Brazil.

Planned enrollment
10th of 33
600 · median 370
Started
2024
with 5 others
Phase 2/3
4 of 35
1 open now
Primary completion
2028-08
later than 11 of 15 live
Registered
26th of 35
by date

Among the 35 studies in Squamous Cell Carcinoma of Head and Neck with a site in Brazil, this one is the 10th largest by planned enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2024, is one of 4 in phase 2/3, reaches primary completion later than 11 of the 15 other live ones, and was the 26th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

7 of the 35 studies in Squamous Cell Carcinoma of Head and Neck with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Squamous Cell Carcinoma of Head and Neck with a site in Brazil, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically-confirmed R/M HNSCC that is considered incurable by local therapy.

    • Should not have had prior systemic therapy administered in the recurrent or setting. Systemic therapy which was completed more than 6 months prior to randomization if given as part of multimodal treatment for locally advanced disease is allowed.
    • The eligible primary tumor locations are the oropharynx, oral cavity, hypopharynx, and larynx.
  • expression level Combined Positive Score (CPS) ≥ 1.
  • Participants with oropharyngeal cancer must have human papillomavirus (HPV) status from tumor tissue.
  • according to 1.1 as determined by the Investigator.
  • Tumor samples (archival or fresh tumor ) are required. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
  • Recovery to baseline or ≤ Grade 1 severity ( v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  • Age 18 years (or the legal age of consent in your country, if higher than 18) or older on the day of consent.
  • (ECOG) performance status of 0-1.
  • Adequate organ and marrow function.

Exclusion criteria

Exclusion Criteria:

  • Nasopharynx, salivary gland or occult primary site (regardless of p16 status).
  • Has disease that is suitable for local therapy administered with curative intent.
  • Has received prior therapy with zanzalintinib, any , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
  • \< 3 months.
  • Had progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
  • Radiation therapy for bone within 2 weeks, any other radiation therapy within 4 weeks prior to randomization.
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to randomization.
  • Positive surface antigen (HBsAg) test.
  • Positive virus (HCV) antibody test.
  • Major surgery (eg, GI surgery, removal or of brain metastasis) within 8 weeks prior to randomization. Complete wound healing from major or minor surgery must have occurred at least prior to randomization.
  • interval calculated by the Fridericia formula (QTcF) > 480 ms per (ECG) within 28 days before randomization.
  • Pregnant or lactating females.
  • Administration of a live, attenuated vaccine within 30 days before randomization.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Zanzalintinib + Pembrolizumab

    Subjects with R/M HNSCC will receive zanzalintinib + pembrolizumab

    Drug: Zanzalintinib · Biological: Pembrolizumab

  • Placebo comparator
    Zanzalintinib-Matched Placebo + Pembrolizumab

    Subjects with R/M HNSCC will receive zanzalintinib-matched placebo + pembrolizumab

    Drug: Zanzalintinib-matched Placebo · Biological: Pembrolizumab

Interventions

  • Specified doses on specified days

    Also known as: XL092

  • DrugZanzalintinib-matched Placebo

    Specified doses on specified days

    Also known as: XL092-matched Placebo

  • BiologicalPembrolizumab

    Specified doses on specified days

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)

    Defined as the time from randomization to the earlier of either radiographic progressive disease (PD) per RECIST 1.1 as determined by the BICR or death from any cause

    Time frame: Approximately 33 months after the first subject is randomized

  2. Overall Survival (OS)

    Defined as the time from randomization to death due to any cause

    Time frame: Approximately 50 months after the first subject is randomized

Secondary outcomes

  1. PFS per RECIST 1.1 by Investigator

    Defined as the time from randomization to the earlier of either radiographic PD per RECIST 1.1 as determined by the Investigator or death from any cause

    Time frame: Approximately 33 months after the first subject is randomized

  2. Objective Response Rate (ORR) per RECIST 1.1 by the BICR and Investigator

    Defined as the proportion of subjects with the best overall response of complete response (CR) or partial response (PR) per RECIST 1.1 as determined by the BICR and Investigator

    Time frame: Approximately 33 months after the first subject is randomized

  3. Duration of Response (DOR) Per RECIST 1.1 by BICR and Investigator

    Defined as the time from the first documentation of objective response (subsequently confirmed at a visit ≥ 28 days later) to disease progression or death due to any cause

    Time frame: Approximately 33 months after the first subject is randomized

07

Study locations

168 sites
  • Exelixis Clinical Site #2
    Fullerton, California 92835, United States
  • Exelixis Clinical Site #1
    Orange City, Florida 32763, United States
  • Exelixis Clinical Site #163
    Tampa, Florida 33612-9497, United States
  • Exelixis Clinical Site #123
    Athens, Georgia 30607, United States
  • Exelixis Clinical Site #82
    Atlanta, Georgia 30322, United States
  • Exelixis Clinical Site #19
    Chicago, Illinois 60611, United States
  • Exelixis Clinical Site #62
    Des Moines, Iowa 50309, United States
  • Exelixis Clinical Site #100
    Iowa City, Iowa 52242, United States
  • Exelixis Clinical Site #4
    St Louis, Missouri 63110, United States
  • Exelixis Clinical Site #148
    Lebanon, New Hampshire 03756, United States
  • Exelixis Clinical Site #158
    Camden, New Jersey 08103, United States
  • Exelixis Clinical Site #3
    Shirley, New York 11967, United States
  • Exelixis Clinical Site #95
    Durham, North Carolina 27710, United States
  • Exelixis Clinical Site #117
    Wilson, North Carolina 27893, United States
  • Exelixis Clinical Site #43
    Roanoke, Virginia 24014, United States
  • Exelixis Clinical Site #73
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Exelixis Clinical Site #91
    Buenos Aires, C1428AQK, Argentina
  • Exelixis Clinical Site # 47
    Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
  • Exelixis Clinical Site #53
    Ciudad Autonoma de Buenos Aire, C1056ABJ, Argentina
  • Exelixis Clinical Site #93
    Córdoba, X5000JHQ, Argentina
  • Exelixis Clinical Site #64
    Córdoba, X5008HHW, Argentina
  • Exelixis Clinical Site #157
    Pergamino, B2700CPM, Argentina
  • Exelixis Clinical Site #92
    Santa Fe, S3000FFU, Argentina
  • Exelixis Clinical Site #57
    Port Macquarie, New South Wales 2444, Australia
  • Exelixis Clinical Site # 46
    Adelaide, 5000, Australia
  • Exelixis Clinical Site #154
    Bedford Park, 5042, Australia
  • Exelixis Clinical Site #137
    Camperdown, NSW 2050, Australia
  • Exelixis Clinical Site #39
    Murdoch, 6150, Australia
  • Exelixis Clinical Site #156
    Linz, 4010, Austria
  • Exelixis Clinical Site #42
    Salzburg, 5020, Austria
  • Exelixis Clinical Site #166
    Vienna, 1090, Austria
  • Exelixis Clinical Site #22
    Brussels, 1200, Belgium
  • Exelixis Clinical Site #106
    Charleroi, 6000, Belgium
  • Exelixis Clinical Site #14
    Libramont, 6800, Belgium
  • Exelixis Clinical Site #37
    Sint-Niklaas, 9100, Belgium
  • Exelixis Clinical Site #68
    Passo Fundo, Rio Grande do Sul 99010-260, Brazil
  • Exelixis Clinical Site #90
    Porto Alegre, Rio Grande do Sul 91350 200, Brazil
  • Exelixis Clinical Site #110
    Jaú, São Paulo 17210 190, Brazil
  • Exelixis Clinical Site #65
    Santo André, São Paulo 09060-650, Brazil
  • Exelixis Clinical Site #83
    São José do Rio Preto, São Paulo 15090 000, Brazil
  • Exelixis Clinical Site #116
    Barretos, 14784 400, Brazil
  • Exelixis Clinical Site #75
    Curitiba, 80810 050, Brazil
  • Exelixis Clinical Site #101
    Curitiba, 81520 060, Brazil
  • Exelixis Clinical Site #97
    Porto Alegre, 90110 270, Brazil
  • Exelixis Clinical Site #102
    Recife, 50070 225, Brazil
  • Exelixis Clinical Site #87
    Rio de Janeiro, 20230 130, Brazil
  • Exelixis Clinical Site #76
    São Paulo, 01323 030, Brazil
  • Exelixis Clinical Site #77
    São Paulo, 01525 001, Brazil
  • Exelixis Clinical Site #67
    São Paulo, 04014-002, Brazil
  • Exelixis Clinical Site #98
    São Paulo, 05403 900, Brazil
  • Exelixis Clinical Site #88
    São Paulo, 1221020, Brazil
  • Exelixis Clinical Site #25
    Plovdiv, 4004, Bulgaria
  • Exelixis Clinical Site #94
    Rousse, 7002, Bulgaria
  • Exelixis Clinical Site #15
    Sofia, 1330, Bulgaria
  • Exelixis Clinical Site #11
    Sofia, 1527, Bulgaria
  • Exelixis Clinical Site #54
    Sofia, 1797, Bulgaria
  • Exelixis Clinical Site #33
    Santiago, 13127, Chile
  • Exelixis Clinical Site #52
    Santiago, 7500859, Chile
  • Exelixis Clinical Site #38
    Santiago, 8331143, Chile
  • Exelixis Clinical Site #109
    Santiago, 8940577, Chile
  • Exelixis Clinical Site #50
    Talca, 3465586, Chile
  • Exelixis Clinical Site #51
    Valdivia, 5090000, Chile
  • Exelixis Clinical Site #40
    Viña del Mar, 2540364, Chile
  • Exelixis Clinical Site #96
    Barranquilla, 80020, Colombia
  • Exelixis Clinical Site #152
    Bogotá, 129, Colombia
  • Exelixis Clinical Site #103
    Floridablanca, 6810002, Colombia
  • Exelixis Clinical Site #146
    Pasto, 520001, Colombia
  • Exelixis Clinical Site #149
    Pereira, 660001, Colombia
  • Exelixis Clinical Site #49
    Nový Jičín, 74101, Czechia
  • Exelixis Clinical Site #58
    Olomouc, 77900, Czechia
  • Exelixis Clinical Site #151
    Prague, 10 10034, Czechia
  • Exelixis Clinical Site #34
    Prague, 14059, Czechia
  • Exelixis Clinical Site #48
    Prague, 15006, Czechia
  • Exelixis Clinical Site #36
    Prague, 18081, Czechia
  • Exelixis Clinical Site #28
    Marseille, Bouches-du-Rhône 13005, France
  • Exelixis Clinical Site #16
    Bordeaux, Gironde 33075, France
  • Exelixis Clinical Site #44
    Rennes, Ille Et Vilaine 35042, France
  • Exelixis Clinical Site #108
    Saint Priest En Jarez, Pays de la Loire Region 42270, France
  • Exelixis Clinical Site #70
    Lyon, Rhone 69008, France
  • Exelixis Clinical Site #107
    Le Mans, Sarthe 72000, France
  • Exelixis Clinical Site #66
    Villejuif, Val De Marne 94805, France
  • Exelixis Clinical Site #144
    Dijon, 21000, France
  • Exelixis Clinical Site #141
    Grenoble, 09 38043, France
  • Exelixis Clinical Site #140
    Lille, 59000, France
  • Exelixis Clinical Site #26
    Paris, 75013, France
  • Exelixis Clinical Site #112
    Pierre-Bénite, 69004, France
  • Exelixis Clinical Site #105
    Poitiers, 86021, France
  • Exelixis Clinical Site #167
    Giessen, 35392, Germany
  • Exelixis Clinical Site #155
    Athens, 11527, Greece
  • Exelixis Clinical Site #129
    Athens, 12462, Greece
  • Exelixis Clinical Site #159
    Larissa, 41500, Greece
  • Exelixis Clinical Site #120
    Thessaloniki, 54622, Greece
  • Exelixis Clinical Site #150
    Thessaloniki, 56403, Greece
  • Exelixis Clinical Site #128
    Thessaloniki, 57001, Greece
  • Exelixis Clinical Site #125
    Budapest, 1083, Hungary
  • Exelixis Clinical Site #99
    Kecskemét, 6000, Hungary
  • Exelixis Clinical Site #131
    Salgótarján, 3100, Hungary
  • Exelixis Clinical Site #147
    Szekszárd, 7100, Hungary
  • Exelixis Clinical Site #132
    Haifa, 3109601, Israel
  • Exelixis Clinical Site #85
    Haifa, 3436212, Israel

Showing the first 100 of 168 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Saba NF, Harrington K, Licitra L, Machiels JP, He C, Jew T, Andrianov V, Haddad R. STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC. Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18. PubMed 40248950 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Aug 2028, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 13, 2023
StartActual
Jun 7, 2024
Primary completionEst.
Aug 2028
CompletionEst.
Mar 2029
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06082167
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Jun 7, 2024
Primary completion
Aug 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion